Register Now
Panelists:
Nathan Buchbinder
Chief Strategy OfficerProscia
View Bio
Panelist
Nathan Buchbinder
Nathan Buchbinder is co-founder and chief strategy officer at Proscia, where he guides the company in continuing to set the direction for the future of pathology. He sits at the intersection of the company’s customers, products, and the broader digital pathology community, overseeing strategic growth opportunities and leading Proscia’s participation in industry initiatives. Buchbinder has a bachelor’s degree in Biomedical Engineering from Johns Hopkins University and a master’s degree in Biomedical Innovation and Development from the Georgia Institute of Technology
Close
Ritida Nanda
Senior Product Marketing ManagerProscia
View Bio
Panelist
Ritida Nanda
Ritida Nanda is a senior product marketing manager at Proscia, where she leads strategic positioning of the company’s digital pathology solutions for life sciences organizations. She focuses on demonstrating how pathology data can accelerate drug discovery and advance precision medicine for pharmaceutical and biotech companies. Nanda holds a bachelor’s degree in Business from Santa Clara University.
Close
Broadcast Date: Thursday, December 4, 2025Time: 08:00 PST, 11:00 EST, 16:00 GMTBringing a new therapy to market takes years and costs billions, leaving biopharma under increasing pressure to compress development timelines. Overcoming that inertia requires rethinking traditional approaches to identifying biomarkers, generating evidence, and scaling trials, which remain slow and fragmented. Pathology—long the foundation of diagnosis—is emerging as a critical and underutilized source of data and insight that can fuel every stage of therapeutic development and delivery.In this GEN webinar, Nathan Buchbinder and Ritida Nanda will discuss how Proscia Aperture, powered by the Concentriq® enterprise pathology platform and global network of diagnostic labs, transforms routine clinical data into a real-time intelligence engine for biopharma. During the webinar, you will learn how Aperture connects multimodal pathology data, specifically whole slide tissue images, molecular test results, and clinical context, across a global diagnostic network. They will also discuss how pathology data captured and analyzed at diagnosis can reveal novel biomarkers and validate targets, accelerate patient recruitment and optimize trial design, generate real-world evidence that reflects true patient diversity and disease progression, and support collaboration between diagnostic labs and biopharma. By attending this webinar, you will:Understand how pathology data expands biopharma’s precision medicine toolbox with real-time diagnostic signals.See practical use cases for digital pathology and AI across the drug development continuum—from discovery to commercialization.Learn how a global network of diagnostic labs can support scalable, patient-centric trial recruitment and real-world evidence generation.Gain insights from experts on how pathology intelligence is transforming biopharma’s approach to discovery, development, and access.A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelists.Produced with support from:The post Pathology Data: The Missing Link in Accelerating Precision Medicine appeared first on GEN – Genetic Engineering and Biotechnology News.
